Is CytoDyn Inc. (CYDY) a Buy, Sell, or Hold?
OTC : CYDY
CytoDyn Inc.
$0.214 USD
$0 (0.0%)
- Volume
- 298.36K
- Average Volume
- 1.93M
- Market Capitalization
- $293.12M
- P/E Ratio
- -6.69
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.40
- Year Low
- $0.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$0.03
- Current Ratio
- $0.37
Company Overview
OTC
Jacob Lalezari
Biotechnology
Healthcare
CYDY
13
US
USD
Liquidity Metrics
-0.26
0.37
0.37
0.31
-0.03
Sales & Valuation
-$5.92M
-49.55
-2.62
-16.30
-0.01
Profitability
$0.0018
$3.74M
655.73%
655.73%
36.98%
-209.73%
P/E Metrics
-6.69
0.02
0.02
Analyst Price Target & Rating
2/5
2 Analysts
%
Financial Health Scores
-77.53
2/9
-$31.99M
$18.5M
$122.78M
-$38.05M
Key Metrics (TTM)
$304.7M
-51.50
-8.01
0.37
36.98%
104.43%
-14.22%
-6.13%
-289381 days
Company Executives
| Name | Title |
|---|---|
| Robert E. Hoffman | Chief Financial Officer |
| Max Lataillade | Senior Vice President & Head of Clinical Development |
| Scott Hansen | Head of Research & Basic Science |
| Bernie Cunningham | Vice President of Operations |
| Jacob Lalezari | Chief Executive Officer |
| Tyler Blok | Chief Legal Officer & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About CytoDyn Inc. (OTC:CYDY) Stock
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington. ...
2026-07-22 08:00:00
TACOMA, Wash., July 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP announces proposed class action settlement on behalf of purchasers of CytoDyn Inc. common stock between March 27, 2020 and March 30, 2022 (OTCQB: CYDY): UNITED STATES DISTRICT COURTWESTERN DISTRICT OF WASHINGTON AT TACOMA BRIAN JOE COURTER, COURTER AND SONS LLC, DIANE M.
2026-06-11 08:30:00
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple therapeutic indications, today announced that the first patient has been dosed in a Phase 2a clinical study evaluating leronlimab in patients with Alzheimer's disease, in collaboration with Weill Cornell Medicine. The study, known as SALIENT-AD (Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease), is a Phase 2a, open-label, proof-of-concept study designed to evaluate the safety and biological activity of leronlimab in approximately 10 to 20 patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease.
CytoDyn to Present at the LD Micro Invitational XVI
2026-05-15 08:30:00
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m.
2026-05-01 05:41:47
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
2026-04-27 08:30:00
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development
Frequently Asked Questions
-
What is the current CytoDyn Inc. (CYDY) stock price?
-
CytoDyn Inc.(OTC:CYDY) stock price is $0.214 in the last trading session. During the trading session, CYDY stock reached the peak price of $0.4 while $0.19 was the lowest point it dropped to. The percentage change in CYDY stock occurred in the recent session was 0.0% while the dollar amount for the price change in CYDY stock was $0.
-
CYDY's industry and sector of operation?
-
The OTC listed CYDY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYDY?
-
Robert E. Hoffman | Chief Financial Officer
Max Lataillade | Senior Vice President & Head of Clinical Development
Scott Hansen | Head of Research & Basic Science
Bernie Cunningham | Vice President of Operations
Jacob Lalezari | Chief Executive Officer -
How many employees does CYDY have?
-
Number of CYDY employees currently stands at 13. CYDY operates from 1111 Main Street, Vancouver, WA 98660, US.
-
Link for CYDY official website?
-
Official Website of CYDY is: https://www.cytodyn.com
-
How do I contact CYDY?
-
CYDY could be contacted at phone #360 980 8524 and can also be accessed through its website. CYDY operates from 1111 Main Street, Vancouver, WA 98660, US.
-
How many shares of CYDY are traded daily?
-
The average number of CYDY shares traded daily for last 3 months was 1.93M.
-
What is the market cap of CYDY currently?
-
The market value of CYDY currently stands at $293.12M with its latest stock price at $0.214